{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:07Z","timestamp":1772165587849,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011890","name":"Wesley Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018853","name":"Prince Charles Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018853","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Health Research Board of Ireland"},{"name":"Biomedicine international training research programme for excellent clinician-scientists"},{"name":"European Union\u2019s research and innovation programme"},{"DOI":"10.13039\/100010434","name":"\u201cla Caixa\u201d Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The influence of renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors on the critically ill COVID-19 patients with pre-existing hypertension remains uncertain. This study examined the impact of previous use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the critically ill COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from an international, prospective, observational cohort study involving 354 hospitals spanning 54 countries were included. A cohort of 737 COVID-19 patients with pre-existing hypertension admitted to intensive care units (ICUs) in 2020 were targeted. Multi-state survival analysis was performed to evaluate in-hospital mortality and hospital length of stay up to 90\u00a0days following ICU admission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 737 patients were included\u2014538 (73%) with pre-existing hypertension had received ACEi\/ARBs before ICU admission, while 199 (27%) had not. Cox proportional hazards model showed that previous ACEi\/ARB use was associated with a decreased hazard of in-hospital death (HR, 0.74, 95% CI 0.58\u20130.94). Sensitivity analysis adjusted for propensity scores showed similar results for hazards of death. The average length of hospital stay was longer in ACEi\/ARB group with 21.2\u00a0days (95% CI 19.7\u201322.8\u00a0days) in ICU and 6.7\u00a0days (5.9\u20137.6\u00a0days) in general ward compared to non-ACEi\/ARB group with 16.2\u00a0days (14.1\u201318.6\u00a0days) and 6.4\u00a0days (5.1\u20137.9\u00a0days), respectively. When analysed separately, results for ACEi or ARB patient groups were similar for both death and discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In critically ill COVID-19 patients with comorbid hypertension, use of ACEi\/ARBs prior to ICU admission was associated with a reduced risk of in-hospital mortality following adjustment for baseline characteristics although patients with ACEi\/ARB showed longer length of hospital stay.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Clinical trial registration<\/jats:italic>\n                      The registration number: ACTRN12620000421932; The date of registration: 30, March 2020; The URL of the registration:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.australianclinicaltrials.gov.au\/anzctr\/trial\/ACTRN12620000421932\">https:\/\/www.australianclinicaltrials.gov.au\/anzctr\/trial\/ACTRN12620000421932<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-022-02565-1","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:03:08Z","timestamp":1648047788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of renin\u2013angiotensin\u2013aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Kei","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon P.","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nchafatso","family":"Obonyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinesh","family":"Appadurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ciullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryta","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott T.","family":"Worku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Helms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Ohshimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafsah A.","family":"Juzar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacky Y.","family":"Suen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi Li","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh C.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"COVID-19 Critical Care Consortium Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi Li","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacky Y.","family":"Suen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi J.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Laffey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddy","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Chiumello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyaa","family":"Elhazmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Ichiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair","family":"Nichol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline Yeung","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Marwali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grad","family":"Dip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Grasselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"2565_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"2565_CR2","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.","journal-title":"Lancet Respir Med"},{"key":"2565_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","volume":"38","author":"M Esler","year":"2020","unstructured":"Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38:781\u20132.","journal-title":"J Hypertens"},{"key":"2565_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8.","journal-title":"Cell"},{"key":"2565_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X, Lou K, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u20133. https:\/\/doi.org\/10.1038\/s41586-020-2012-7.","journal-title":"Nature"},{"key":"2565_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281-292.e6. https:\/\/doi.org\/10.1016\/j.cell.2020.02.058.","journal-title":"Cell"},{"key":"2565_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11906-008-0076-0","volume":"10","author":"MJ Soler","year":"2008","unstructured":"Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep. 2008;10:410\u20134.","journal-title":"Curr Hypertens Rep"},{"key":"2565_CR8","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMe2012924","volume":"382","author":"JA Jarcho","year":"2020","unstructured":"Jarcho JA, Ingelfinger JR, Hamel MB, D\u2019Agostino RB, Harrington DP. Inhibitors of the renin\u2013angiotensin\u2013aldosterone system and covid-19. N Engl J Med. 2020;382:2462\u20134.","journal-title":"N Engl J Med"},{"key":"2565_CR9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671\u201381.","journal-title":"Circ Res"},{"key":"2565_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"T Guo","year":"2020","unstructured":"Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2020.1017.","journal-title":"JAMA Cardiol"},{"key":"2565_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.dsx.2020.03.016","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr Clin Res Rev. 2020;14:283\u20137. https:\/\/doi.org\/10.1016\/j.dsx.2020.03.016.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2565_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cardfail.2020.04.013","volume":"26","author":"B Bozkurt","year":"2020","unstructured":"Bozkurt B, Kovacs R, Harrington B. Joint HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. J Cardiac Fail. 2020;26:370. https:\/\/doi.org\/10.1016\/j.cardfail.2020.04.013.","journal-title":"J Cardiac Fail"},{"key":"2565_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-041417","author":"G Li Bassi","year":"2020","unstructured":"Li Bassi G, Suen J, Barnett AG, Corley A, Millar J, Fanning J, et al. Design and rationale of the COVID-19 Critical Care Consortium international, multicentre, observational study. BMJ Open. 2020. https:\/\/doi.org\/10.1136\/bmjopen-2020-041417.","journal-title":"BMJ Open"},{"key":"2565_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"key":"2565_CR15","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","volume":"35","author":"PC Austin","year":"2016","unstructured":"Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35:5642\u201355.","journal-title":"Stat Med"},{"key":"2565_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12874-020-01082-z","volume":"20","author":"D Hazard","year":"2020","unstructured":"Hazard D, Kaier K, Von Cube M, Grodd M, Bugiera L, Lambert J, et al. Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach. BMC Med Res Methodol. 2020;20:66. https:\/\/doi.org\/10.1186\/s12874-020-01082-z.","journal-title":"BMC Med Res Methodol"},{"key":"2565_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-020-00880-6","volume":"22","author":"R Baral","year":"2020","unstructured":"Baral R, White M, Vassiliou VS. Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients. Curr Atheroscler Rep. 2020;22:1\u20139. https:\/\/doi.org\/10.1007\/s11883-020-00880-6.","journal-title":"Curr Atheroscler Rep"},{"key":"2565_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.dsx.2020.04.019","volume":"14","author":"E Cure","year":"2020","unstructured":"Cure E, Cumhur CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes Metab Syndr Clin Res Rev. 2020;14:349\u201350. https:\/\/doi.org\/10.1016\/j.dsx.2020.04.019.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2565_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/joim.13101","volume":"288","author":"A Aleksova","year":"2020","unstructured":"Aleksova A, Ferro F, Gagno G, Cappelletto C, Santon D, Rossi M, et al. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2)\u2014Is there any scientific evidence for controversy? J Intern Med. 2020;288:410\u201321. https:\/\/doi.org\/10.1111\/joim.13101.","journal-title":"J Intern Med"},{"key":"2565_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.amjcard.2007.08.050","volume":"101","author":"R Shah","year":"2008","unstructured":"Shah R, Wang Y, Foody JAM. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients \u226565 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol. 2008;101:217\u201322.","journal-title":"Am J Cardiol"},{"key":"2565_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1042\/CS20130436","volume":"126","author":"CA McKinney","year":"2014","unstructured":"McKinney CA, Fattah C, Loughrey CM, Milligan G, Nicklin SA. Angiotensin-(1\u20137) and angiotensin-(1\u20139): function in cardiac and vascular remodelling. Clin Sci. 2014;126:815\u201327.","journal-title":"Clin Sci"},{"key":"2565_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/acel.13168","volume":"19","author":"J Chen","year":"2020","unstructured":"Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell. 2020;19:1\u201312. https:\/\/doi.org\/10.1111\/acel.13168.","journal-title":"Aging Cell"},{"key":"2565_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E De Wit","year":"2016","unstructured":"De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523\u201334.","journal-title":"Nat Rev Microbiol"},{"key":"2565_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81:537\u201340. https:\/\/doi.org\/10.1002\/ddr.21656.","journal-title":"Drug Dev Res"},{"key":"2565_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/HYPERTENSIONAHA.119.13197","volume":"75","author":"WT Hsu","year":"2020","unstructured":"Hsu WT, Galm BP, Schrank G, Hsu TC, Lee SH, Park JY, et al. Effect of renin\u2013angiotensin\u2013aldosterone system inhibitors on short-term mortality after sepsis: a population-based cohort study. Hypertension. 2020;75:483\u201391. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13197.","journal-title":"Hypertension"},{"key":"2565_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000397","author":"TD Corr\u00eaa","year":"2014","unstructured":"Corr\u00eaa TD, Jeger V, Pereira AJ, Takala J, Djafarzadeh S, Jakob SM. Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis. Crit Care Med. 2014. https:\/\/doi.org\/10.1097\/CCM.0000000000000397.","journal-title":"Crit Care Med"},{"key":"2565_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/CCM.0b013e3181958d91","volume":"37","author":"S Hagiwara","year":"2009","unstructured":"Hagiwara S, Iwasaka H, Matumoto S, Hidaka S, Noguchi T. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit Care Med. 2009;37:626\u201333. https:\/\/doi.org\/10.1097\/CCM.0b013e3181958d91.","journal-title":"Crit Care Med"},{"key":"2565_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin\u2013angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for Coronavirus Disease 2019 (COVID-19) infection in Wuhan. China JAMA Cardiol. 2020;5:825\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2020.1624.","journal-title":"China JAMA Cardiol"},{"key":"2565_CR29","doi-asserted-by":"publisher","unstructured":"Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, B Pearson CA, et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med. 2020;18:270. https:\/\/doi.org\/10.1186\/s12916-020-01726-3.","DOI":"10.1186\/s12916-020-01726-3"},{"key":"2565_CR30","doi-asserted-by":"publisher","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertens (Dallas, Tex 1979). 2018;71:E13\u2013115. https:\/\/doi.org\/10.1161\/HYP.0000000000000065.","DOI":"10.1161\/HYP.0000000000000065"},{"key":"2565_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/nejmoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693\u2013704. https:\/\/doi.org\/10.1056\/nejmoa2021436.","journal-title":"N Engl J Med"},{"key":"2565_CR32","unstructured":"Bethesda. COVID-19 treatment guidelines. National Institutes of Health. 2020. https:\/\/www.covid19treatmentguidelines.nih.gov\/de."}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02565-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02565-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02565-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:06:40Z","timestamp":1648048000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02565-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2565"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02565-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-898264\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"11 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This Study was conducted as a cardiac sub-study of the COVID-19-CCC\/ECMOCARD registry [\n                      \n                      ]. All methods were performed in accordance with the protocols, Declaration of Helsinki and the Principles of Good Clinical Practice. As this study was a multicentre international study, each participating site obtained local ethics committee approval. The host facilities, The Alfred Hospital, Melbourne and The Prince Charles Hospital, Brisbane, got ethical approval from The Alfred Hospital Ethics Committee (Human Research Ethics Committee Code: EC00315). Waivers of informed consent were granted for all patients as all data are collected routinely. A complete summary of ethics and regulatory approvals is included in the main COVID-19-CCC protocol [\n                      \n                      ]. De-identified data were collected for enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GLB and JFF received research funds, through their affiliated institution, from Fisher & Paykel for studies related to high-flow oxygen therapy. The remaining authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}